Lundbeck to measure brain with microscopic camera in new partnership

In a research collaboration with the US-based Inscopix, Lundbeck hopes to find some answers to the question of why it's so difficult to develop drugs against psychiatric disorders.

The US Food & Drug Administration's recent approval of Biogen's Alzheimer drug, Aduhelm, has sparked debate and controversy over how to measure the efficacy of medications against psychiatric and neurological disorders.

Lundbeck is acutely aware of this. The pharmaceutical company has previously experienced many setbacks in mid and late phase trials after preclininical and early clinical trials showed promising results.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs